This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Look: Discussing the Phase 1/2 study to assessing Mezigdomide in patients with multiple myeloma
Ticker(s): BMYWho's the expert?
Institution: Case Western Reserve University School of Medicine
- Clinical Professor, Department of Medicine, School of Medicine and Member, Immune Oncology Program, Case Comprehensive Cancer Center
- Research interests are focused on three major areas: 1) early phase cancer therapeutics, cellular and immunotherapies for blood cancers and other non-malignant disorders; 2) laboratory-based translational researches in normal and cancer stem cell signaling profiles and pre-clinical animal models for therapeutics.
- treats over 50 patients a year with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
- familiar with results from the final analysis of the phase 3 ALPINE trial
Interview GoalThis call will focus on the results rom the the Phase 1/2 study to assess the safety, PK and efficacy of Mezigdomide (CC-92480) monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
